We claim:

1. A therapeutic agent for bladder cancer comprising Compound 1 or a pharmaceutically acceptable salt thereof:



(Compound 1).

2. The therapeutic agent of claim 1, wherein said pharmaceutically acceptable salt is a diammonium salt.

3. A pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof:



(Compound 1)

and a pharmaceutically acceptable excipient for use in treating bladder cancer.

4. Use of Compound 1 or a pharmaceutically acceptable salt thereof for preparation of a pharmaceutical composition for treating bladder cancer:



(Compound 1).

5. A therapeutic agent for bladder cancer in a patient, the therapeutic agent comprising Compound 1, a pharmaceutically acceptable salt of Compound 1, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt of Compound 1:



(Compound 1),

wherein the patient is identified as having bladder cancer treatable by Compound 1, a pharmaceutically acceptable salt of Compound 1, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt of Compound 1.

6. The therapeutic agent of claim 5, wherein said patient is identified as having a bladder cancer treatable by Compound 1, a pharmaceutically acceptable salt of Compound 1, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt of Compound 1, by a presence of a REF STING variant allele in the patient.

7. A therapeutic agent for bladder cancer in a patient having a REF STING allele, the therapeutic agent comprising Compound 1, a pharmaceutically acceptable salt of Compound 1, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt of Compound 1:



(Compound 1).

8. A therapeutic agent for bladder cancer in a patient having a WT STING allele, the therapeutic agent comprising Compound 1, a pharmaceutically acceptable salt of Compound 1, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt of Compound 1:



(Compound 1).

9. A therapeutic agent for bladder cancer in a patient having a AQ STING allele, the therapeutic agent comprising Compound 1, a pharmaceutically acceptable salt of Compound 1, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt of Compound 1:



(Compound 1).

10. A therapeutic agent for bladder cancer in a patient having a HAQ STING allele, the therapeutic agent comprising Compound 1, a pharmaceutically acceptable salt of Compound 1, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt of Compound 1:



(Compound 1).

11. A therapeutic agent for bladder cancer comprising a STING agonist.

12. The therapeutic agent of any one of claims 1-2 or 5-11, or the pharmaceutical composition of claim 3, wherein the therapeutic agent or the pharmaceutical composition is formulated for intravesicular administration.

13. The therapeutic agent of any one of claim 1-2 or 5-11, or the pharmaceutical composition of claim 3,wherein the bladder cancer is non-muscle invasive bladder cancer.